Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CHI-560,CHI-563,CHI-564,CHI-565
Therapeutic Area : Undisclosed
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 03, 2023
Lead Product(s) : CHI-560,CHI-563,CHI-564,CHI-565
Therapeutic Area : Undisclosed
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : James Madison University
Deal Size : Inapplicable
Deal Type : Inapplicable
The Effects of CBD Isolate on Menstrual-Related Symptoms
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 11, 2023
Lead Product(s) : Cannabidiol,Inapplicable
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : James Madison University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tetrahydrocannabinol,Caffeine,Cannabidiol
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Johns Hopkins University
Deal Size : Inapplicable
Deal Type : Inapplicable
The Pharmacodynamics of Cannabinoid-Caffeine Combinations
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
July 28, 2022
Lead Product(s) : Tetrahydrocannabinol,Caffeine,Cannabidiol
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Johns Hopkins University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabis,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Recipient : Johns Hopkins University
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics and Pharmacodynamics of CHI-914 in Healthy Participants
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
April 13, 2022
Lead Product(s) : Cannabis,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Recipient : Johns Hopkins University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidiol,Inapplicable
Therapeutic Area : Musculoskeletal
Study Phase : Phase I
Sponsor : NM Clinical Research & Osteoporosis Center
Deal Size : Inapplicable
Deal Type : Inapplicable
CBD in Postmenopausal Women With Osteopenia
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 07, 2022
Lead Product(s) : Cannabidiol,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase I
Sponsor : NM Clinical Research & Osteoporosis Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tetrahydrocannabivarin,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 27, 2022
Lead Product(s) : Tetrahydrocannabivarin,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CHI-202,Inapplicable
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 30, 2021
Lead Product(s) : CHI-202,Inapplicable
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CHI-554,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : University of Arkansas
Deal Size : Inapplicable
Deal Type : Inapplicable
A Randomized Controlled Test of the Effects of CHI-554 on Fear.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 08, 2020
Lead Product(s) : CHI-554,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : University of Arkansas
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CHI-902,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Centre for Addiction and Mental Health | McMaster University
Deal Size : Inapplicable
Deal Type : Inapplicable
CHI-902 for Treatment of Social Anxiety Disorder
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 11, 2019
Lead Product(s) : CHI-902,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Centre for Addiction and Mental Health | McMaster University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CHI-921,Inapplicable
Therapeutic Area : Sleep
Study Phase : Phase II
Sponsor : Galenova Inc | Algorithme Pharma Inc. | Hôpital du Sacre-Cœur de Montréal | McGill University Health Centre Research Institute | Centre Hospitalier de l'Universite de Montreal
Deal Size : Inapplicable
Deal Type : Inapplicable
Investigation of the Efficacy and Safety of CHI-921 in Insomnia.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 13, 2019
Lead Product(s) : CHI-921,Inapplicable
Therapeutic Area : Sleep
Highest Development Status : Phase II
Sponsor : Galenova Inc | Algorithme Pharma Inc. | Hôpital du Sacre-Cœur de Montréal | McGill University Health Centre Research Institute | Centre Hospitalier de l'Universite de Montreal
Deal Size : Inapplicable
Deal Type : Inapplicable